Invention Grant
- Patent Title: Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
-
Application No.: US16318840Application Date: 2017-07-19
-
Publication No.: US11746152B2Publication Date: 2023-09-05
- Inventor: Stephen S. Yoo , Mien-Chie Hung , Chia-Wei Li , Seung-Oe Lim
- Applicant: STCUBE, INC. , BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Applicant Address: KR TX Seoul
- Assignee: STCUBE, INC.,BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee: STCUBE, INC.,BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee Address: KR Seoul; US TX Austin
- Agency: Ballard Spahr LLP
- International Application: PCT/US2017/042797 2017.07.19
- International Announcement: WO2018/017673A 2018.01.25
- Date entered country: 2019-01-18
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; C07K16/28 ; C07K16/44 ; A61P35/00

Abstract:
Anti-cancer treatment and therapeutic methods are provided in which an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 and blocks binding of PD-L1 to PD-1 is administered to a subject in need in combination with an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, blocks binding of PD-L1 to PD-1 and also promotes internalization and degradation of PD-L1. The anti-cancer methods utilize antibodies that recognize specific epitopes on glycosylated PD-L1 protein, as well as antibodies that exhibit the IPD function of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells expressing PD-L1. Methods in which such antibody combinations are especially useful include cancer and tumor treatments and therapies in which the cancer or tumor is a PD-L1 positive cancer or tumor.
Public/Granted literature
- US20190218297A1 METHODS OF CANCER TREATMENT AND THERAPY USING A COMBINATION OF ANITBODIES THAT BIND GLYCOSYLATED PD-L1 Public/Granted day:2019-07-18
Information query